DeChene Elizabeth Taylor, Kang Peter B, Beggs Alan H
Genetic Counselor and Project Coordinator, Division of Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Director, Electromyography Laboratory, Department of Neurology, Boston Children's Hospital;, Associate Professor of Neurology, Harvard Medical School, Boston, Massachusetts
NOTE: THIS PUBLICATION HAS BEEN RETIRED. THIS ARCHIVAL VERSION IS FOR HISTORICAL REFERENCE ONLY, AND THE INFORMATION MAY BE OUT OF DATE.
Congenital fiber-type disproportion (CFTD) is usually characterized by hypotonia and mild-to-severe generalized muscle weakness at birth or within the first year of life. Although some individuals remain non-ambulatory throughout life, many eventually develop the ability to walk. In more than 90% of affected individuals, muscle weakness is static or improves; in the remainder it is usually slowly progressive. Mild-to-severe respiratory involvement is seen in approximately 30% of affected individuals; respiratory failure may occur at any age. Ophthalmoplegia, ptosis, and facial and/or bulbar weakness with severe limb/respiratory weakness may predict a poor prognosis. Mild-to-severe feeding difficulties occur in nearly 30% of children. Contractures of the hips, knees, ankles, elbows, and fingers occur in approximately 25% and may be present at birth or occur in older persons with decreased mobility secondary to severe weakness. Spinal deformities including scoliosis, kyphoscoliosis, and lordosis are seen in 25% or more of individuals.
DIAGNOSIS/TESTING: Diagnosis is based on a combination of clinical presentation and morphologic features observed on skeletal muscle histology. The pathologic and clinical manifestations of CFTD overlap with other neuromuscular and non-neuromuscular diseases that must be ruled out prior to making a diagnosis of CFTD. To date, pathogenic variants have been identified in six genes: (6% of individuals with CFTD), (unknown), (10%-20%), () (rare), (rare), and (~20%-25% of individuals with CFTD).
For weakness/contractures: physical therapy and occupational therapy (orthotics or splinting, serial casting, or walking supports/wheelchair); regular low-impact exercise, stretching, and submaximal strength training with sufficient rest to avoid exhaustion; for respiratory issues: breathing exercises, chest physiotherapy, seating assessment, immunizations, antibiotics for chest infections, tracheostomy, or ventilatory support; for feeding/swallowing difficulties: speech therapy, and gavage or gastrostomy feedings; orthopedic evaluation for foot deformities, joint contractures, and scoliosis; bracing or spinal fusion based on progression of the spinal curve and effect on pulmonary and motor function; treatment by a cardiologist as needed; orthodontia as needed. Consider precautions for malignant hyperthermia prior to anesthesia; preoperative assessment of pulmonary and cardiac function; consistent joint movement to prevent contractures. Regular monitoring of motor abilities/weakness, pulmonary and cardiac function, and spine for scoliosis (especially in childhood and adolescence). Extended immobilization.
CFTD is a genetically heterogeneous condition that can be inherited in an autosomal recessive, autosomal dominant, or X-linked manner. To date, all identified cases of , , and -related CFTD have been caused by autosomal dominant pathogenic variants while the and -related cases have been associated with autosomal recessive pathogenic variants. related CFTD can be inherited in an autosomal dominant or autosomal recessive manner. and pathogenic variants are often dominant. A large portion of individuals with CFTD represent simplex cases (i.e., a single occurrence in a family). It can be difficult to determine inheritance pattern in the family of a simplex case when a pathogenic variant is not identified through testing of known genes. Prenatal testing for pregnancies at risk for CFTD is possible if the pathogenic variant(s) in a family are known.
注意:本出版物已停用。此存档版本仅用于历史参考,信息可能过时。
先天性纤维类型比例失调(CFTD)通常表现为出生时或出生后第一年内出现肌张力减退和轻至重度全身性肌无力。虽然一些个体终生无法行走,但许多人最终会发展出行走能力。超过90%的受影响个体,肌无力症状稳定或有所改善;其余个体症状通常缓慢进展。约30%的受影响个体出现轻至重度呼吸受累;呼吸衰竭可在任何年龄发生。眼肌麻痹、上睑下垂以及伴有严重肢体/呼吸肌无力的面部和/或延髓肌无力可能预示预后不良。近30%的儿童出现轻至重度喂养困难。髋、膝、踝、肘和手指挛缩发生率约为25%,可能在出生时就存在,或出现在因严重肌无力导致活动能力下降的老年人中。25%或更多个体出现脊柱畸形,包括脊柱侧凸、脊柱后凸和脊柱前凸。
诊断/检测:诊断基于临床表现和骨骼肌组织学观察到的形态学特征。CFTD的病理和临床表现与其他神经肌肉和非神经肌肉疾病重叠,在诊断CFTD之前必须排除这些疾病。迄今为止,已在六个基因中鉴定出致病变异:(约6%的CFTD个体)、(未知)、(约10%-20%)、()(罕见)、(罕见)以及(约20%-25%的CFTD个体)。
针对肌无力/挛缩:物理治疗和职业治疗(矫形器或夹板、连续石膏固定或步行辅助器具/轮椅);定期进行低强度运动、伸展以及次最大强度力量训练,并给予足够休息以避免疲劳;针对呼吸问题:呼吸锻炼、胸部物理治疗、座位评估、免疫接种、用于胸部感染的抗生素、气管切开术或通气支持;针对喂养/吞咽困难:言语治疗,以及管饲或胃造口喂养;对足部畸形、关节挛缩和脊柱侧凸进行骨科评估;根据脊柱侧弯进展情况以及对肺部和运动功能的影响进行支具治疗或脊柱融合术;根据需要由心脏病专家进行治疗;根据需要进行正畸治疗。麻醉前考虑预防恶性高热;术前评估肺部和心脏功能;保持关节持续活动以预防挛缩。定期监测运动能力/肌无力、肺部和心脏功能以及脊柱是否出现脊柱侧凸(尤其是在儿童期和青春期)。避免长期固定。
CFTD是一种遗传异质性疾病,可通过常染色体隐性、常染色体显性或X连锁方式遗传。迄今为止,所有已鉴定的与、和相关的CFTD病例均由常染色体显性致病变异引起,而与和相关的病例与常染色体隐性致病变异有关。相关CFTD可通过常染色体显性或常染色体隐性方式遗传。和致病变异通常为显性。大部分CFTD个体为散发病例(即家族中仅出现一例)。当通过对已知基因的检测未鉴定出致病变异时,很难确定散发病例家族中的遗传模式。如果家族中的致病变异已知,对于有CFTD风险的妊娠可进行产前检测。